# A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

> **NCT00389324** · PHASE2 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 35 (actual)

## Conditions studied

- Immunologic Deficiency Syndrome

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (Human)

## Key facts

- **NCT ID:** NCT00389324
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389324, "A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00389324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*